Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine

Posted Aug 22 2013 8:00pm

Description of Invention:
Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against B. anthracis infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of B. anthracis PA. This technology may be important to any bioterrorism defense strategy.

Applications:
  • Novel anthrax vaccines
  • Post-vaccination screening to determine if anthrax protection is achieved
  • Biodefense


Advantages:
  • May require fewer vaccination follow-ups, while present anthrax vaccines require numerous rounds of injections and boosters for full-effectiveness.
  • Identified peptide sequences, representing regions of PA, elicit an immune response in primate and human sera studies.


Development Status:
  • Pre-clinical
  • In vitro data available


Inventors:
Vera A Semenova (CDC)
Conrad P Quinn (CDC)
Jan Pohl (CDC)
Pavel Svoboda (CDC)


Patent Status:
HHS, Reference No. E-158-2013/2
US, Application No. 13/577,878 filed 08 Aug 2012
PCT, Application No. PCT/US2011/024311 filed 10 Feb 2011



For Licensing Information Please Contact:
Whitney Blair
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: blairw2@mail.nih.gov
Phone: 301-435-4937
Fax: 301-402-0220


Ref No: 2621

Updated: 08/2013

Post a comment
Write a comment:

Related Searches